Abstract
A significant amount of research has been focused on the relationship between hormones and Alzheimers disease. However, the majority of this work has been on estrogen and more recently testosterone. A serendipitous patient encounter led one of us (RLB) to question whether other hormones of the hypothalamic-pituitary-gonadal axis could be playing a role in the pathogenesis of Alzheimers disease. The age-related decline in reproductive function results in a dramatic decrease in serum estrogen and testosterone concentrations and an equally dramatic compensatory increase in serum luteinizing hormone concentrations. Indeed, there is growing evidence that the gonadotropin, luteinizing hormone, which regulates serum estrogen and testosterone concentrations, could be an important causative factor in the development of Alzheimers disease. This review provides information supporting the "gonadotropin hypothesis, " puts forth a novel mechanism of how changes in serum luteinizing hormone concentrations could contribute to the pathogenesis of Alzheimers disease, and discusses potential therapeutic anti-gonadotropin compounds.
Keywords: Luteinizing hormone (LH), follicle-stimulating hormone (FSH), Alzheimer's disease, gonadotropin releasing hormone (GnRH), cell cycle, estrogen
Current Pharmaceutical Design
Title: Antigonadotropins: A Novel Strategy to Halt Alzheimers Disease Progression
Volume: 12 Issue: 6
Author(s): Christopher W. Gregory, Craig S. Atwood, Mark A. Smith and Richard L. Bowen
Affiliation:
Keywords: Luteinizing hormone (LH), follicle-stimulating hormone (FSH), Alzheimer's disease, gonadotropin releasing hormone (GnRH), cell cycle, estrogen
Abstract: A significant amount of research has been focused on the relationship between hormones and Alzheimers disease. However, the majority of this work has been on estrogen and more recently testosterone. A serendipitous patient encounter led one of us (RLB) to question whether other hormones of the hypothalamic-pituitary-gonadal axis could be playing a role in the pathogenesis of Alzheimers disease. The age-related decline in reproductive function results in a dramatic decrease in serum estrogen and testosterone concentrations and an equally dramatic compensatory increase in serum luteinizing hormone concentrations. Indeed, there is growing evidence that the gonadotropin, luteinizing hormone, which regulates serum estrogen and testosterone concentrations, could be an important causative factor in the development of Alzheimers disease. This review provides information supporting the "gonadotropin hypothesis, " puts forth a novel mechanism of how changes in serum luteinizing hormone concentrations could contribute to the pathogenesis of Alzheimers disease, and discusses potential therapeutic anti-gonadotropin compounds.
Export Options
About this article
Cite this article as:
Gregory W. Christopher, Atwood S. Craig, Smith A. Mark and Bowen L. Richard, Antigonadotropins: A Novel Strategy to Halt Alzheimers Disease Progression, Current Pharmaceutical Design 2006; 12 (6) . https://dx.doi.org/10.2174/138161206775474288
DOI https://dx.doi.org/10.2174/138161206775474288 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Towards a “Metabolic” Subtype of Major Depressive Disorder: Shared Pathophysiological Mechanisms May Contribute to Cognitive Dysfunction
CNS & Neurological Disorders - Drug Targets Sirtuin Inhibitors: An Overview from Medicinal Chemistry Perspective
Anti-Cancer Agents in Medicinal Chemistry Overview of Coumarins and its Derivatives: Synthesis and Biological Activity
Letters in Organic Chemistry System Models, Assays and Endpoint Parameters to Evaluate Anticancer Compounds During Preclinical Screening
Current Medicinal Chemistry RUNX2 and Osteosarcoma
Anti-Cancer Agents in Medicinal Chemistry Aberrant Activation of Arachidonic Acid and Eicosanoid Pathways-Targets for Treating Prostate Cancer
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Hsp90 Inhibitor Geldanamycin and Its Derivatives as Novel Cancer Chemotherapeutic Agents
Current Pharmaceutical Design Multifunctional Targeted Radiotherapy System for Induced Tumours Expressing Gastrin-releasing Peptide Receptors
Current Nanoscience Polymers and Biopolymers as Drug Delivery Systems in Nanomedicine
Recent Patents on Nanomedicine Anti-carcinogenic Effect of Cathepsin K Inhibitor, Odanacatib with a Low Dose of Cisplatin Against Human Breast Carcinoma MCF-7 and MDA-MB231 Cells
Current Cancer Therapy Reviews Overview of Systems Biology and Omics Technologies
Current Medicinal Chemistry Association Studies on mtDNA and Parkinson`s Disease Population Discrimination Using the Statistical Classification
Current Bioinformatics Signaling Intermediates (PI3K/PTEN/AKT/mTOR and RAF/MEK/ERK Pathways) as Therapeutic Targets for Anti-Cancer and Anti-Angiogenesis Treatments
Current Signal Transduction Therapy Perinatal Gene Transfer to the Liver
Current Pharmaceutical Design The Hydroxamic Acids as Potential Anticancer and Neuroprotective Agents
Current Medicinal Chemistry FLT3 as a Therapeutic Target in Childhood Acute Leukemia
Current Drug Targets Metabolic Targets of Cardiac HormonesTherapeutic Anti-Cancer Effects
Current Pharmaceutical Design Toxicogenomics
Current Drug Metabolism Physiologic Versus Diabetogenic Effects of Interleukin-1: A Question of Weight
Current Pharmaceutical Design Oncolytic Viruses Driven by Tumor-Specific Promoters
Current Cancer Drug Targets